entertainment -WSS

entertainment

author：fashion 2025-09-27 09:54:44 - browse：86427

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Virtual Event: March of the Biosimilars

leisure time

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Obamacare plans could cover weight loss drugs

Researchers tackle phage therapy hurdles for wider adoption

Asbestos, a deadly carcinogen, banned by EPA

Ukraine seeks to reclaim its role as a hub for clinical trials

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New air purifier tech could be key to improving indoor air quality

FDA warns medical device makers about rise in fabricated data

Sports medicine is finally prioritizing gender equality

Congress may force more Covid

Medical records are filled with copy

Medicare Advantage enrollment grows 7.1% to 33.4 million people

At least 13 dead in Texas as scorching temps continue

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Duchenne breakthrough therapy leaves behind pioneering families

Ukraine seeks to reclaim its role as a hub for clinical trials

explore

Asbestos, a deadly carcinogen, banned by EPA

Obamacare plans could cover weight loss drugs

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

New study raises questions about niacin and heart health

Elevance, SCAN deals highlight health insurer acquisition scrutiny

SCOTUS questions limit to govt efforts to fight misinformation

leisure time

hotspot

leisure time

focus